Clinical diagnostics by Gnothis single-molecule DNA sequencing of patient blood samples
Reference number | |
Coordinator | Gnothis AB |
Funding from Vinnova | SEK 990 000 |
Project duration | May 2018 - June 2020 |
Status | Completed |
Important results from the project
The project has led to a clear next step in introducing a productified version of Gnothis product prototype to clinical clients in locations other than at Karolinska Institutet/Karolinska Sjukhuset. Discussions have been conduced with several university hospitals and other clinical institutions in Sweden and there is a great interest in using Gnothis product.
Expected long term effects
The outcome of the project has led to an increased understanding in the area that the project concerns and in particular has led to that the underlying technology has been further developed to suit the customer´s needs in the best possible way. Also, the project has led to that other potential customers have received information about the technolog aand now has the opportunity to consider purchasing a product version that will be launched as soon as possible.
Approach and implementation
The implementation of the project has proceeded essentially as planned. Analyzes have been conducted at Gnothis premises on an instrument prepared for the purpose to enable execution according to schedule, but this has not led to any negative effects.